About: Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report
Creator	Patel, Ishan Costanzo, Eric Douedi, Steven Mazahir, Usman Akoluk, Arda Flynn, Daniel Upadhyaya, Vandan
Source	Medline; PMC
abstract	Respiratory failure is presumptively caused by microvascular thrombosis in some patients with coronavirus disease 2019 (COVID-19) requiring therapeutic anticoagulation. Anticoagulation treatment may cause life-threatening bleeding complications such as retroperitoneal hemorrhage. To the best of our knowledge, we report first case of a COVID-19 patient treated with therapeutic anticoagulation resulting in psoas hematoma due to lumbar artery bleeding. A 69-year-old patient presented with fever, malaise and progressive shortness of breath to our hospital. He was diagnosed with COVID-19 by RT-PCR. Due to an abnormal coagulation profile, the patient was started on enoxaparin. Over the course of hospitalization, the patient was found to have hypotension with worsening hemoglobin levels. Computed tomography scan of the abdomen and pelvis revealed a large psoas hematoma. Arteriogram revealed lumbar artery bleeding which was treated with embolization. Anticoagulation therapy, while indicated in COVID-19 patients, has its own challenges and guidelines describing dosages and indications in this disease are lacking. Rare bleeding complications such as psoas hematoma should be kept in mind in patients who become hemodynamically unstable, warranting prompt imaging for diagnosis and treatment with arterial embolization, thus eliminating need of surgical intervention.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.14740/jocmr4256
bibo:pmid	32655742
has license	cc-by-nc
sha1sum (hex)	2740f859aa370ee8b3d13c1feb3607996196d7b7
schema:url	https://doi.org/10.14740/jocmr4256
resource representing a document's title	Life-Threatening Psoas Hematoma due to Retroperitoneal Hemorrhage in a COVID-19 Patient on Enoxaparin Treated With Arterial Embolization: A Case Report
has PubMed Central identifier	PMC7331864
has PubMed identifier	32655742
schema:publication	J Clin Med Res
resource representing a document's body	covid:2740f859aa370ee8b3d13c1feb3607996196d7b7#body_text
is schema:about of	named entity 'Hemorrhage' named entity 'Psoas' named entity 'Case Report' named entity 'Case Report' named entity 'Life-Threatening' named entity 'Embolization' named entity 'embolization' named entity 'dimers' named entity 'coagulation' named entity 'supportive measures' named entity 'Critically ill patients' named entity 'retroperitoneal hemorrhage' named entity 'thrombi' named entity 'Physical examination' named entity 'intravenous fluid' named entity 'iliac bone' named entity 'mm Hg' named entity 'retroperitoneal hemorrhage' named entity 'CAD' named entity 'psoas muscle' named entity 'blood pressure' named entity 'hypercoagulable' named entity 'physical examination' named entity 'thrombi' named entity 'dimer' named entity 'PRBC' named entity 'CT scan' named entity 'lumbar artery' named entity 'antithrombotic agents' named entity 'anticoagulation therapy' named entity 'hydroxychloroquine' named entity 'pelvis' named entity 'thrombolytic' named entity 'major bleeding' named entity 'catheterization' named entity 'COVID' named entity 'anticoagulated' named entity 'embolization' named entity 'heparin' named entity 'Anticoagulation treatment' named entity 'Pro-inflammatory cytokines' named entity 'chest X-ray' named entity 'lumbar arteries' named entity 'D-dimer' named entity 'inflammation' named entity 'embolization' named entity 'proinflammatory cytokines' named entity 'case report' named entity 'anticoagulants' named entity 'Computed tomography' named entity 'vasopressor' named entity 'inflammatory cytokines' named entity 'therapeutic effect' named entity 'embolization' named entity 'mm Hg' named entity 'COVID-19' named entity 'fever' named entity 'COVID' named entity 'COVID' named entity 'PRBC' named entity 'IL-1' named entity 'heparin' named entity 'COVID' named entity 'pneumonia' named entity 'hemorrhage' named entity 'anticoagulant therapy' named entity 'ultrasound' named entity 'aspirin' named entity 'aspirin' named entity 'enoxaparin' named entity 'stroke' named entity 'anticoagulation therapy' named entity 'complex disease' named entity 'coagulopathies' named entity 'extravasation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software